galop: Comparative Study of GangTrainer GT1, Lokomat and Conventional Physiotherapy

Sponsor
Research Department for Neurorehabilitation South Tyrol (Other)
Overall Status
Suspended
CT.gov ID
NCT01146587
Collaborator
Privatklinik Villa Melitta (Other), Hochzirl Hospital (Other), Krankenhaus Bozen (Other), Krankenhaus Brixen (Other), Krankenhaus Meran (Other), Krankenhaus Bruneck (Other), Claudiana Landesfachhochschule (Other)
120
7
3
66
17.1
0.3

Study Details

Study Description

Brief Summary

The GangTrainer GT I and the Lokomat have proven their effectiveness on stroke Patients, but a comparison on the same controlled study population has not been made so far. Aim of the study will not only be to establish which device will work better on acute, non ambulatory stroke Patients in terms of regain of gait ability and motor function, but also clinical matters, like the efficacy of the treatment period. As a result of the trial it should be highlighted which kind of therapy has to be suggested for Patients comparable to the study population. A significant better outcome of one device in regard to the other will suggest to use one device more than the other for future treatments.

Condition or Disease Intervention/Treatment Phase
  • Device: GangTrainer GT1
  • Device: Lokomat
  • Other: Conventional Physiotherapy
N/A

Detailed Description

A total of 120 Patients will be enroled in the study and divided into 2 treatment and 1 control group. Enroled Patients will all be first supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks.

Theywill undergo either robotic treatment with the Gangtrainer GT1 or the Lokomat in one of the 2 treatment groups for 30 minutes of gross therapy time every workday for a 8 weeks period if they are in the treatment group, or conventional physiokinetherapy for 30 minutes of gross therapy time every workday for a 8 weeks period if they are in the control group.

Primary outcome will be the Functional Ambulation Category (FAC) assessed at enrolment, after 4 weeks after 8 weeks and at 6 months follow up.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Robot Assisted Therapy for Acute Stroke Patients: a Comparative Study of GangTrainer GT I, Lokomat System and Conventional Physiotherapy
Study Start Date :
Aug 1, 2010
Anticipated Primary Completion Date :
Dec 1, 2015
Anticipated Study Completion Date :
Feb 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: GangTrainer GT1

First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Gangtrainer GT1 for 30 minutes of gross therapy time every workday for a 8 weeks period

Device: GangTrainer GT1
30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
Other Names:
  • Group A
  • Experimental: Lokomat

    First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Lokomat for 30 minutes of gross therapy time every workday for a 8 weeks period

    Device: Lokomat
    30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
    Other Names:
  • Group B
  • Active Comparator: Conventional Physiotherapy

    First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo a conventional physiokinetherapeutic treatment session for 30 minutes of gross therapy time every workday for a 8 weeks period

    Other: Conventional Physiotherapy
    60 minutes of Conventional Physiotherapy every workday for 8 weeks
    Other Names:
  • Group C
  • Outcome Measures

    Primary Outcome Measures

    1. Functional Ambulation Category (FAC) [after 8 weeks]

    Secondary Outcome Measures

    1. Barthel Index (BI) [at week 1]

    2. Barthel Index (BI) [after 4 weeks]

    3. Barthel Index (BI) [after 8 weeks]

    4. Barthel Index (BI) [after 24 weeks]

    5. Rivermead Mobility Index (RMI) [at week 1]

    6. Rivermead Mobility Index (RMI) [after 4 weeks]

    7. Rivermead Mobility Index (RMI) [after 8 weeks]

    8. Rivermead Mobility Index (RMI) [after 24 weeks]

    9. 10 metres Walking Test [at week 1]

    10. 10 metres Walking Test [after 4 weeks]

    11. 10 metres Walking Test [after 8 weeks]

    12. 10 metres Walking Test [after 24 weeks]

    13. 6 Minutes Walking Test on the Floor [at week 1]

    14. 6 Minutes Walking Test on the Floor [after 4 weeks]

    15. 6 Minutes Walking Test on the Floor [after 8 weeks]

    16. 6 Minutes Walking Test on the Floor [after 24 weeks]

    17. 6 Minutes Walking Test on the Treadmill with Body Weight Support [at week 1]

    18. 6 Minutes Walking Test on the Treadmill with Body Weight Support [after 4 weeks]

    19. 6 Minutes Walking Test on the Treadmill with Body Weight Support [after 8 weeks]

    20. 6 Minutes Walking Test on the Treadmill with Body Weight Support [after 24 weeks]

    21. Medical Research Council (MRC) [at week 1]

    22. Medical Research Council (MRC) [after 4 weeks]

    23. Medical Research Council (MRC) [after 8 weeks]

    24. Medical Research Council (MRC) [after 24 weeks]

    25. Modified Ashworth Scale (mAS) [at week 1]

    26. Modified Ashworth Scale (mAS) [after 4 weeks]

    27. Modified Ashworth Scale (mAS) [after 8 weeks]

    28. Modified Ashworth Scale (mAS) [after 24 weeks]

    29. Rivermead Visual Gait Assessment (RVGA) [at week 1]

    30. Rivermead Visual Gait Assessment (RVGA) [after 8 weeks]

    31. Rivermead Visual Gait Assessment (RVGA) [after 24 weeks]

    32. EuroQol 5 Dimensions (EQ-5D) [at week 1]

    33. EuroQol 5 Dimensions (EQ-5D) [after 8 weeks]

    34. EuroQol 5 Dimensions (EQ-5D) [after 24 weeks]

    35. modified emory Functional Ambulation Profile (meFAP) [at week 1]

    36. modified emory Functional Ambulation Profile (meFAP) [after 4 weeks]

    37. modified emory Functional Ambulation Profile (meFAP) [after 8 weeks]

    38. modified emory Functional Ambulation Profile (meFAP) [after 24 weeks]

    39. Functional Ambulation Category (FAC) [at week 1]

    40. Functional Ambulation Category (FAC) [after 4 weeks]

    41. Functional Ambulation Category (FAC) [after 24 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 79 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • First supratentorial stroke (ischaemic, haemorrhagic or ICH) resulting in a hemiparesis

    • Interval from stroke 3 - 12 weeks

    • Non ambulatory (FAC < 3)

    • Free sitting on bedside for 1 minute, both feet on the floor, ev. holding on bedside by hands

    • Barthel Index 25 - 65

    Exclusion Criteria:
    • Unstable cardiovascular system (in case of doubt, only after approval by a internist)

    • Manifested heart diseases like labile compensated cardiac insufficiency (NYHA III), angina pectoris, myocardial infarction 120 days before study onset, cardiomyopathy, severe cardiac arrhythmia

    • Severe joint misalignment (severe constriction of movement for hip, knee and/or ankle: more than 20° fixed hip and knee extension deficit, or more than 20° fixed plantar flexion of the ankle

    • Severe cognitive dysfunction, which does not allow for comprehension of the aims of this study

    • Severe neurological or orthopaedic diseases (like polio, Parkinson´s disease), which massively affect the mobility

    • Deep vein thrombosis

    • Severe osteoporosis

    • Malignant tumour diseases

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hochzirl Hospital Hochzirl Tirol Austria 6170
    2 Claudiana Landesfachhochschule Bozen Südtirol Italy 39100
    3 Krankenhaus Bozen Bozen Südtirol Italy 39100
    4 Privatklinik Villa Melitta Bozen Südtirol Italy 39100
    5 Krankenhaus Brixen Brixen Südtirol Italy 39042
    6 Krankenhaus Bruneck Bruneck Südtirol Italy 39031
    7 Krankenhaus Meran Meran Südtirol Italy 39012

    Sponsors and Collaborators

    • Research Department for Neurorehabilitation South Tyrol
    • Privatklinik Villa Melitta
    • Hochzirl Hospital
    • Krankenhaus Bozen
    • Krankenhaus Brixen
    • Krankenhaus Meran
    • Krankenhaus Bruneck
    • Claudiana Landesfachhochschule

    Investigators

    • Principal Investigator: Andreas Waldner, MD, Privatklinik Villa Melitta
    • Study Chair: Christopher Tomelleri, MSc, Privatklinik Villa Melitta
    • Study Director: Leopold Saltuari, MD PhD, Hochzirl Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Research Department for Neurorehabilitation South Tyrol
    ClinicalTrials.gov Identifier:
    NCT01146587
    Other Study ID Numbers:
    • GT-LK-PT
    First Posted:
    Jun 17, 2010
    Last Update Posted:
    Jun 8, 2015
    Last Verified:
    Jun 1, 2015
    Keywords provided by Research Department for Neurorehabilitation South Tyrol
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 8, 2015